¼¼°èÀÇ Ç÷¼ÒÆÇ ½ÃÀå
Blood Platelets
»óǰÄÚµå : 1777874
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 386 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,204,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,612,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ç÷¼ÒÆÇ ½ÃÀåÀº 2030³â±îÁö 67¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 57¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Ç÷¼ÒÆÇ ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 2.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 67¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¾ÆÆä·¹½Ã½º À¯·¡ Ç÷¼ÒÆÇÀº CAGR 3.5%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 41¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀüÇ÷ À¯·¡ Ç÷¼ÒÆÇ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 2.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 15¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.7%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ Ç÷¼ÒÆÇ ½ÃÀåÀº 2024³â¿¡ 15¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 13¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 5.7%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 1.1%¿Í 2.3%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.6%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Ç÷¼ÒÆÇ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çö´ë ÇコÄɾ¼­ Ç÷¼ÒÆÇ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

Ç÷¼ÒÆÇÀº Ç÷¾× ÀÀ°í, »óó Ä¡À¯, ¸é¿ª ¹ÝÀÀ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ¿Ü»ó Ä¡·á, ¼ö¼ú, ¾Ï Ä¡·á, Ç÷¾× Áúȯ µî ´Ù¾çÇÑ Ä¡·á¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Ç÷¼ÒÆÇ ¼öÇ÷Àº È­Çпä¹ýÀ̳ª Àå±â À̽ÄÀ» ¹Þ´Â ȯÀÚ, Ç÷¼ÒÆÇ °¨¼ÒÁõ(Ç÷¼ÒÆÇ °¨¼ÒÁõ) ȯÀÚ¿¡°Ô´Â »ý¸í°ú Á÷°áµÇ´Â Ä¡·á¹ýÀÔ´Ï´Ù. ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, ¸¸¼ºÇ÷¾×ÁúȯÀÇ À¯º´·ü Áõ°¡´Â Àü ¼¼°è º´¿ø, Ç÷¾×ÀºÇà, ¼öÇ÷¼¾ÅÍ¿¡¼­ Ç÷¼ÒÆÇ ¼ö¿ä¸¦ Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

Ç÷¼ÒÆÇ ¼öÇ÷ÀÇ Çʿ伺Àº È­Çпä¹ýÀ̳ª ¹æ»ç¼± Ä¡·á°¡ °ñ¼ö ±â´ÉÀ» ¾ïÁ¦Çϰí Ç÷¼ÒÆÇ »ý¼ºÀ» °¨¼Ò½ÃŰ´Â Á¾¾çÇп¡¼­ ƯÈ÷ ³ô½À´Ï´Ù. ¶ÇÇÑ, ¼ö¼ú°ú º¹ÀâÇÑ ÀÇ·á °³ÀÔ Áõ°¡µµ Ç÷¼ÒÆÇ ¼öÇ÷¿¡ ´ëÇÑ ÀÇÁ¸µµ¸¦ ³ôÀÌ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Ç÷¼ÒÆÇ ¼öÇ÷ÀÌ ¸Å¿ì Áß¿äÇÔ¿¡µµ ºÒ±¸Çϰí, Ç÷¼ÒÆÇÀº º¸Á¸ ±â°£ÀÌ Âª°í(5-7ÀÏ), ¼¼±Õ ¿À¿°ÀÇ À§ÇèÀÌ Àֱ⠶§¹®¿¡ Ç÷¼ÒÆÇ ¼öÇ÷¿¡´Â °íÀ¯ÇÑ °úÁ¦°¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ÇコÄÉ¾î ½Ã½ºÅÛÀº Ç÷¼ÒÆÇ º¸Á¸ ±â¼ú °³¼±, º´¿øÃ¼ Àú°¨ ±â¼ú, ±×¸®°í ¾ÈÁ¤ÀûÀÌ°í ¾ÈÀüÇÑ Ç÷¼ÒÆÇ °ø±ÞÀ» º¸ÀåÇϱâ À§ÇÑ °íµµÀÇ ±âÁõÀÚ ¸ðÁý Àü·«¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº Ç÷¼ÒÆÇÀÇ ¼öÁý, ÀúÀå, Ȱ¿ëÀ» ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

Ç÷¼ÒÆÇ ¼öÁý, º¸Á¸, ¼öÇ÷ ¹æ¹ýÀÇ Áß¿äÇÑ Çõ½ÅÀº Ç÷¼ÒÆÇ Ä¡·áÀÇ È¿À²¼º°ú ¾ÈÀü¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ ¹ßÀü Áß Çϳª´Â °ø¿©ÀڷκÎÅÍ Ç÷¼ÒÆÇÀ» Á÷Á¢ äÃëÇÏ¿© ³ª¸ÓÁö Ç÷¾× ¼ººÐÀ» ´Ù½Ã µ¹·ÁÁÖ´Â ¾ÆÆç·¹½Ã½º ±â¼úÀÇ »ç¿ëÀÔ´Ï´Ù. ¾ÆÆç·¹½Ã½º À¯·¡ Ç÷¼ÒÆÇÀº ÀüÇ÷ À¯·¡ Ç÷¼ÒÆÇº¸´Ù ¼öÀ²ÀÌ ³ô°í, ¸é¿ª¹ÝÀÀÀÇ À§ÇèÀÌ °¨¼ÒÇϸç, º¸Á¸±â°£ÀÌ ±æ¾î ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, äÇ÷ ÀåºñÀÇ ÀÚµ¿È­·Î äÇ÷ È¿À²ÀÌ Çâ»óµÇ¾î Ç÷¾×ÀºÇàÀº ´õ ÀûÀº ¾çÀÇ Ç÷¾×À¸·Î ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

Ç÷¼ÒÆÇ ±â¼úÀÇ ¶Ç ´Ù¸¥ ȹ±âÀûÀÎ ¹ßÀüÀº Àڿܼ±(UV)°ú È­ÇÐÀû Ä¡·á¸¦ »ç¿ëÇÏ¿© Ç÷¼ÒÆÇ À¯´Ö ³» ¹ÙÀÌ·¯½º, ¹ÚÅ׸®¾Æ ¹× ±âŸ ¿À¿° ¹°ÁúÀ» ºñȰ¼ºÈ­ÇÏ´Â º´¿øÃ¼ °¨¼Ò ½Ã½ºÅÛÀÇ °³¹ßÀÔ´Ï´Ù. INTERCEPT¿Í MirasolÀ» Æ÷ÇÔÇÑ ÀÌ·¯ÇÑ ±â¼úÀº Ç÷¼ÒÆÇ ±â´ÉÀ» À¯ÁöÇϸ鼭 °¨¿° À§ÇèÀ» °¨¼Ò½ÃÄÑ ¼öÇ÷ÀÇ ¾ÈÀü¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³Ãµ¿ º¸Á¸µÈ Ç÷¼ÒÆÇ°ú ÇÕ¼º Ç÷¼ÒÆÇ ´ëüǰ¿¡ ´ëÇÑ ¿¬±¸µµ Ȱ¹ßÈ÷ ÁøÇàµÇ°í ÀÖÀ¸¸ç, Ç÷¼ÒÆÇÀÇ º¸Á¸ ±â°£À» ¿¬ÀåÇϰí ÀÀ±Þ ÀÇ·á ¹× ±º ÀÇ·á¿¡¼­ÀÇ È°¿ëµµ¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. AI ±â¹Ý Àç°í °ü¸® ½Ã½ºÅÛÀº Ç÷¼ÒÆÇ °ø±Þ¸ÁÀ» ÃÖÀûÈ­ÇÏ¿© ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü°¡ Ç÷¼ÒÆÇ °¡¿ë¼ºÀ» ´õ Àß °ü¸®ÇÏ°í ³¶ºñ¸¦ ÁÙ¿© Àû½Ã¿¡ È¿À²ÀûÀÎ ¼öÇ÷À» ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

Ç÷¼ÒÆÇ »ê¾÷ÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â ½ÃÀå µ¿ÇâÀº?

Ç÷¾× ¹× Á¾¾ç ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â Ç÷¼ÒÆÇ ½ÃÀåÀÇ ¼ºÀåÀ» À̲ô´Â °¡Àå Áß¿äÇÑ Æ®·»µå Áß ÇϳªÀÔ´Ï´Ù. ¾Ï Áø´Ü Áõ°¡¿Í Ç÷¼ÒÆÇ ¼öÇ÷À» ÇÊ¿ä·Î ÇÏ´Â Àû±ØÀûÀÎ Ä¡·á ÇÁ·ÎÅäÄÝ·Î ÀÎÇØ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, ¿Ü»óÄ¡·á¼¾ÅÍ ¹× °í³­À̵µ ¼ö¼úÀÇ È®´ë·Î ÀÎÇØ ƯÈ÷ ÀÀ±ÞÀÇ·á ¹× ±¸±ÞÀÇ·á ÇöÀå¿¡¼­´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â Ç÷¼ÒÆÇ °ø±Þ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¶Ç ´Ù¸¥ ÁÖ¿ä Æ®·»µå´Â ¸ÂÃãÇü ÀÇ·á¿Í Á¤¹ÐÀÇ·á·ÎÀÇ ÀüȯÀÔ´Ï´Ù. À¯ÀüÀÚ °Ë»ç ¹× ºÐÀÚÁø´ÜÀÇ ¹ßÀüÀ¸·Î Èñ±ÍÇ÷¾×Áúȯ ȯÀÚ, À̽ÄȯÀÚ µî ƯÁ¤ ȯÀÚ±º¿¡ ¸ÂÃá Ç÷¼ÒÆÇ Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, Ç÷¼ÒÆÇ ±âÁõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀûÀýÇÑ Ç÷¼ÒÆÇ °ø±ÞÀ» À¯ÁöÇϱâ À§ÇØ ÀÚ¹ßÀû ÇåÇ÷À» Àå·ÁÇϰí, Ç¥ÀûÈ­µÈ ±âÁõÀÚ ¸ðÁý ÇÁ·Î±×·¥À¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. Ç÷¾× ÀºÇà¿¡ AI¿Í ºí·ÏüÀÎ ±â¼úÀ» ÅëÇÕÇÏ¿© ±âÁõÀÚ ÃßÀû, ¼öÇ÷ ¸ð´ÏÅ͸µ, Àç°í °ü¸®¸¦ ´õ¿í °£¼ÒÈ­Çϰí Ç÷¼ÒÆÇ ºÎÁ·À» ÁÙÀÌ°í ¼öÇ÷ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

Ç÷¼ÒÆÇ ½ÃÀåÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Ç÷¼ÒÆÇ ½ÃÀåÀÇ ¼ºÀåÀº Ç÷¼ÒÆÇ ¼öÇ÷ÀÌ ÇÊ¿äÇÑ Áúº´ÀÇ À¯º´·ü Áõ°¡, Ç÷¼ÒÆÇ º¸Á¸ ¹× ó¸®ÀÇ ¹ßÀü, ¼¼°è ÀÇ·á ÀÎÇÁ¶óÀÇ È®Àå µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â ¹éÇ÷º´, ¸²ÇÁÁ¾, °ñ¼ö ÁúȯÀÇ Ä¡·á°¡ Ç÷¼ÒÆÇ Áö¿ø¿¡ Å©°Ô ÀÇÁ¸ÇÏ´Â Á¾¾çÇÐ ¹× Ç÷¾×ÇÐ ºÐ¾ß¿¡¼­ Ç÷¼ÒÆÇ ¼öÇ÷¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ¶ÇÇÑ, °í·ÉÈ­µµ Ç÷¼ÒÆÇ ÀÌ¿ë Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °í·É ȯÀÚ´Â ½ÉÇ÷°ü ÁúȯÀ̳ª ¿Ü°úÀû ¼ö¼ú µî ¼öÇ÷ÀÌ ÇÊ¿äÇÑ »óÅ¿¡ ºüÁö±â ½±±â ¶§¹®ÀÔ´Ï´Ù.

½ÃÀåÀ» Çü¼ºÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ÃËÁø¿äÀÎÀº ¹ÙÀÌ¿À Á¦Á¶¿Í Ç÷¼ÒÆÇ ´ëüÁ¦ÀÇ ¹ßÀüÀÔ´Ï´Ù. ½ÇÇè½Ç¿¡¼­ ¹è¾çµÈ Ç÷¼ÒÆÇ°ú Àΰø Ç÷¼ÒÆÇ ¸ð¹æ ³ª³ëÀÔÀÚ¿¡ ´ëÇÑ Á¶»ç´Â Ç÷¼ÒÆÇÀÇ °¡¿ë¼ºÀ» È®´ëÇÏ°í °ø±Þ¸ÁÀÇ Á¦¾àÀ» ±Øº¹ÇÒ ¼ö ÀÖ´Â »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇåÇ÷À» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ±âÁõÀÚ ¼±º° ±â¼úÀÇ ¹ßÀüÀº º¸´Ù ¾ÈÀüÇϰí È¿À²ÀûÀÎ Ç÷¼ÒÆÇ äÃ븦 º¸ÀåÇϰí ÀÖ½À´Ï´Ù. ÇコÄÉ¾î ½Ã½ºÅÛÀÌ ¼öÇ÷ÀÇ ¾ÈÀü¼º, È¿À²¼º, Á¢±Ù¼ºÀ» ¿ì¼±½ÃÇÔ¿¡ µû¶ó Ç÷¼ÒÆÇ ¼ö¿ä´Â Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, Àü ¼¼°èÀûÀ¸·Î Ç÷¼ÒÆÇ ¼öÁý, ÀúÀå, Ä¡·á¿ëµµ¿¡ ´ëÇÑ ±â¼ú Çõ½ÅÀÌ ´õ¿í °¡¼ÓÈ­µÉ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

ºÎ¹®

Ç÷¼ÒÆÇ À¯Çü(¾ÆÆä·¹½Ã½º À¯·¡ Ç÷¼ÒÆÇ, ÀüÇ÷ À¯·¡ Ç÷¼ÒÆÇ), ¿ëµµ(Ç÷¼ÒÆÇ °¨¼ÒÁõ ¿ëµµ, Ç÷¾× Á¾¾ç ¿ëµµ, ÁÖ¼ú±â ÀûÀÀÁõ ¿ëµµ, Ç÷¿ìº´ ¿ëµµ, Ç÷¼ÒÆÇ ±â´É Àå¾Ö, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø ÃÖÁ¾ ¿ëµµ, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) ÃÖÁ¾ ¿ëµµ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Blood Platelets Market to Reach US$6.7 Billion by 2030

The global market for Blood Platelets estimated at US$5.7 Billion in the year 2024, is expected to reach US$6.7 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Apheresis Derived Platelets, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Whole-Blood Derived Platelets segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 5.7% CAGR

The Blood Platelets market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.1% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Blood Platelets Market - Key Trends & Drivers Summarized

Why Is the Demand for Blood Platelets Increasing in Modern Healthcare?

Blood platelets play a crucial role in clotting, wound healing, and immune responses, making them essential in various medical treatments, including trauma care, surgeries, cancer therapies, and hematologic disorders. Platelet transfusions are a lifesaving intervention for patients undergoing chemotherapy, organ transplants, or those with conditions such as thrombocytopenia (low platelet count). The increasing prevalence of cancer, autoimmune diseases, and chronic blood disorders has significantly driven the demand for blood platelets in hospitals, blood banks, and transfusion centers worldwide.

The need for platelet transfusions is particularly high in oncology, where chemotherapy and radiation treatments often suppress bone marrow function, leading to decreased platelet production. Additionally, the rise in surgical procedures and complex medical interventions has contributed to the growing reliance on platelet transfusions. Despite their critical importance, blood platelets present unique challenges due to their short shelf life (5-7 days) and the risk of bacterial contamination. To address these challenges, healthcare systems are investing in improved platelet storage techniques, pathogen reduction technologies, and advanced donor recruitment strategies to ensure a stable and safe platelet supply.

How Are Technological Advancements Enhancing Blood Platelet Collection, Storage, and Utilization?

Significant innovations in platelet collection, storage, and transfusion practices are improving the efficiency and safety of platelet therapy. One of the most notable advancements is the use of apheresis technology, which allows for the direct collection of platelets from a donor while returning the remaining blood components. Apheresis-derived platelets are preferred over whole blood-derived platelets due to their higher yield, reduced risk of immune reactions, and longer shelf life. Additionally, automation in apheresis machines has improved collection efficiency, enabling blood banks to meet increasing demand with fewer donations.

Another breakthrough in platelet technology is the development of pathogen reduction systems, which use ultraviolet (UV) light and chemical treatments to inactivate viruses, bacteria, and other contaminants in platelet units. These technologies, including INTERCEPT and Mirasol, are enhancing transfusion safety by reducing the risk of infections while preserving platelet function. Additionally, research into cryopreserved platelets and synthetic platelet substitutes is gaining momentum, with the potential to extend platelet shelf life and improve accessibility in emergency and military medicine. As AI-driven inventory management systems optimize platelet supply chains, healthcare providers can better manage platelet availability and reduce wastage, ensuring timely and efficient transfusions.

Which Market Trends Are Driving Growth in the Blood Platelets Industry?

The rising incidence of hematologic and oncologic diseases is one of the most significant trends driving growth in the blood platelets market. With increasing cancer diagnoses and aggressive treatment protocols requiring platelet transfusions, demand is expected to grow consistently. Additionally, the expansion of trauma care centers and advanced surgical procedures has heightened the need for reliable platelet supplies, particularly in emergency and critical care settings.

Another key trend influencing the market is the shift toward personalized and precision medicine. Advances in genetic testing and molecular diagnostics are enabling tailored platelet therapies for specific patient populations, such as those with rare blood disorders or transplant recipients. Additionally, increasing awareness about platelet donation has led to targeted donor recruitment programs, encouraging voluntary apheresis donations to maintain an adequate platelet supply. The integration of AI and blockchain technology in blood banking is further streamlining donor tracking, transfusion monitoring, and inventory management, reducing platelet shortages and improving transfusion outcomes.

What Are the Key Growth Drivers Shaping the Future of the Blood Platelets Market?

The growth in the blood platelets market is driven by several key factors, including the increasing prevalence of diseases requiring platelet transfusions, advancements in platelet storage and processing, and the expansion of global healthcare infrastructure. One of the primary growth drivers is the rising demand for platelet transfusions in oncology and hematology, where treatments for leukemia, lymphoma, and bone marrow disorders heavily rely on platelet support. Additionally, the aging population is contributing to increased platelet utilization, as elderly patients are more prone to conditions that require transfusions, such as cardiovascular diseases and surgical interventions.

Another crucial driver shaping the market is the advancement of biomanufacturing and platelet substitutes. Research into lab-grown platelets and artificial platelet-mimicking nanoparticles is opening new possibilities for extending platelet availability and overcoming supply chain limitations. Furthermore, government initiatives promoting blood donation and advancements in donor screening technologies are ensuring safer and more efficient platelet collection practices. As healthcare systems prioritize transfusion safety, efficiency, and accessibility, the demand for blood platelets is expected to rise, driving further innovation in collection, storage, and therapeutic applications worldwide.

SCOPE OF STUDY:

The report analyzes the Blood Platelets market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Platelet Type (Apheresis Derived Platelets, Whole-Blood Derived Platelets); Application (Thrombocytopenia Application, Hemato-Oncology Application, Perioperative Indications Application, Hemophilia Application, Platelet Function Disorders, Other Applications); End-Use (Hospitals End-Use, Ambulatory Surgical Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â